Division of Novartis AG
Latest From Ciba-Geigy Pharmaceuticals
Intercept is aiming to file obeticholic acid for accelerated approval in two liver disease indications and is mining clinical outcomes data to support new surrogate endpoints with the help of a clinical network dubbed the “Supergroup.”
Undaunted by a spate of negative news, Ranbaxy CEO Arun Sawhney says his mandate is clear: to build a strong reputation for Ranbaxy. In a discussion with PharmAsia News, Sawhney says he regrets the errors of the past that led to quality lapses, but says changes have been made to avoid similar fumbles in the future.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Novartis AG
- Senior Management
Douglas Watson, Pres.
William Sheldon, SVP, Marketing
Jefferey F McKelvy, PhD, VP, Development
- Contact Info
Phone: (908) 277-5000
556 Morris Avenue
Summit, NJ 07901
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.